secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001493152-24-018333
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs Q1 net loss $6.3M; revenue drops to $3.6M; explores sale of Pharmaloz
--------------------------------------------------------------------------------

- Net loss of $6.3M ($0.07 loss per share) vs net income of $0.6M ($0.03 EPS) in Q1 2023.
- Revenue declined 81% to $3.6M from $19.3M, driven by zero COVID-19 testing vs 120K tests year ago.
- Pharmaloz Manufacturing exploring strategic alternatives including potential sale; signed two deals worth >$5M annual additional revenue.
- BE-Smart esophageal cancer test on track for H2 2024 commercialization; Project ZenQ-AI launched using AI for cancer therapy.
- Cash at April 30: $4.6M; raised $2.5M via receivables securitization and $3.6M from partial investment sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315224018333/0001493152-24-018333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315224018333/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer